Atara Biotherapeutics, Inc. (ATRA) Financials

NASDAQ Currency in USD Disclaimer

$13.33

north_east $1.13 (9.26%)
Day's range
$12.16
Day's range
$13.39

ATRA Income statement / Annual

Last year (2023), Atara Biotherapeutics, Inc.'s total revenue was $8.57 M, a decrease of 86.51% from the previous year. In 2023, Atara Biotherapeutics, Inc.'s net income was -$276.13 M. See Atara Biotherapeutics, Inc.�s key income statements, including revenue, expenses, profit, and income.

Period FY-2023 FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016 FY-2015 FY-2014
Period Ended 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Operating Revenue $8.57 M $63.57 M $20.34 M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost of Revenue $8.89 M $14.57 M $11.38 M $9.87 M $8.11 M $3.78 M $956,000.00 $383,000.00 $48,000.00 $0.00
Gross Profit -$313,000.00 $49.01 M $8.96 M -$9.87 M -$8.11 M -$3.78 M -$956,000.00 -$383,000.00 -$48,000.00 $0.00
Gross Profit Ratio -0.04 0.77 0.44 0 0 0 0 0 0 0
Research and Development Expenses $224.79 M $272.53 M $282.00 M $244.65 M $216.10 M $167.46 M $81.21 M $56.51 M $41.62 M $15.45 M
General & Administrative Expenses $50.91 M $71.55 M $78.80 M $64.40 M $79.58 M $69.65 M $40.33 M $24.73 M $16.83 M $12.71 M
Selling & Marketing Expenses -$1.11 M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Selling, General & Administrative Expenses $49.80 M $71.55 M $78.80 M $64.40 M $79.58 M $69.65 M $40.33 M $24.73 M $16.83 M $12.71 M
Other Expenses $0.00 -$700,000.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $1.07 M
Operating Expenses $275.69 M $344.09 M $360.80 M $309.05 M $295.68 M $237.11 M $121.53 M $81.24 M $58.45 M $28.16 M
Cost And Expenses $284.58 M $344.09 M $360.80 M $309.05 M $295.68 M $237.11 M $121.53 M $81.24 M $58.45 M $28.16 M
Interest Income $5.43 M $1.99 M $367,000.00 $2.45 M $4.72 M $6.37 M $2.03 M $2.20 M $1.22 M $125,000.00
Interest Expense $5.29 M $1.99 M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Depreciation & Amortization $4.83 M $14.57 M $11.38 M $9.87 M $8.11 M $3.78 M $956,000.00 $383,000.00 $48,000.00 $6,000.00
EBITDA -$266.00 M -$213.72 M -$331.12 M -$296.74 M -$282.86 M -$233.33 M -$120.58 M -$80.86 M -$58.40 M -$28.15 M
EBITDA Ratio -31.03 -5.2 -16.74 0 0 0 0 0 0 0
Operating Income Ratio -32.19 -4.41 -16.74 0 0 0 0 0 0 0
Total Other Income/Expenses Net -$105,000.00 $52.22 M $367,000.00 $2.45 M $4.72 M $6.37 M $2.03 M $2.20 M $1.22 M $125,000.00
Income Before Tax -$276.11 M -$228.29 M -$340.10 M -$306.61 M -$290.96 M -$230.74 M -$119.51 M -$79.04 M -$57.23 M -$28.03 M
Income Before Tax Ratio -32.21 -3.59 -16.72 0 0 0 0 0 0 0
Income Tax Expense $15,000.00 $12,000.00 $46,000.00 $15,000.00 $12,000.00 -$44,000.00 -$14,000.00 $10,000.00 -$9,000.00 -$25,000.00
Net Income -$276.13 M -$2.28 B -$3.40 B -$3.07 B -$2.91 B -$2.31 B -$1.19 B -$790.49 M -$572.21 M -$280.06 M
Net Income Ratio -32.21 -35.91 -167.23 0 0 0 0 0 0 0
EPS -65.18 -55.96 -90.78 -103.63 -141.78 -131.64 -100.03 -68.78 -55.92 -140.42
EPS Diluted -65.18 -55.96 -90.78 -103.63 -141.78 -131.64 -100.03 -68.78 -55.92 -140.42
Weighted Average Shares Out $4.24 M $4.08 M $3.75 M $2.96 M $2.05 M $1.75 M $1.19 M $1.15 M $1.02 M $199,440.00
Weighted Average Shares Out Diluted $4.24 M $4.08 M $3.75 M $2.96 M $2.05 M $1.75 M $1.19 M $1.15 M $1.02 M $199,440.00
Link